Vaccine Info

ZyCoV-D COVID-19 Vaccine

Authored by
Last reviewed
May 11, 2021

ZyCoV-D COVID-19 Vaccine Description

ZyCoV-D is India's first indigenously developed DNA vaccine candidate against COVID-19. The ZyCoV-D vaccine candidate is being developed by Zydus Cadila and approved by the Drugs Controller General of India (DCGI) to conduct Phase III clinical trial to the Department of BioteBiotechnology.

ZyCov-D is being developed on a DNA platform using a non-replicating and non-integrating plasmid carrying the novel coronavirus gene, making it very safe. The DNA platform is known to have better vaccine stability and lower cold chain requirements, which would make it easier to store and transport to remote parts of the country.

DNA vaccines are composed of bacterial plasmids with a gene encoding for the protein of interest and transcription promoter and terminator. The plasmid gains entry in multiple cells such as myocytes, keratinocytes, and antigen-presenting cells (APCs). It enters the nucleus as an episome without getting integrated into the host cell DNA.

Using the host cell’s transcription and translation machinery, the inserted gene gets translated into antigen. A protein expressed by plasmid-transfected cells is likely to be expressed within the cell and folded in its native configuration. The antigen is recognized by APCs and further induces antibodies and cellular response.

The National Biopharma Mission has supported the ZyCov-D vaccine candidate under the Biotechnology Industry Research Assistance Council, a PSU under the DBT was issued.

The Accession Number is DB15892.

Zydus Cadila is headquartered in Ahmedabad, India, Zydus Corporate Park, Scheme No. 63, Survey No. 536, Nr. Vaishnodevi Circle, S.G. Highway, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, Sikkim in India and the USA, and Brazil. The Zydus Research Centre is the dedicated research arm of the Zydus Group. With its team of over 400 research professionals, ZRC spearheads the group’s quest of creating healthier and happier communities globally.

ZyCoV-D COVID-19 Vaccine Indication

ZyCoV-D COVID-19 Vaccine candidate is indicated to prevent COVID-19, the disease caused by the SARS-CoV-2 virus.

ZyCoV-D COVID-19 Vaccine News

May 10, 2021 - Zydus Wellness Ltd. announced results for the fourth quarter ended March 31, 2021. The company reported 23.9% growth in consolidated net sales, which stood at Rs. 6008 mn.

April 23, 2021 - Reuters reported Cadila Healthcare has started producing its COVID-19 vaccine, for which it will soon seek emergency use authorization. The company may produce 240 million vaccine doses a year.

April 22, 2021 - Local media reported the company is conducting phase 3 efficacy trials on a three-dose regimen of its DNA plasmid technology-based Covid-19 vaccine.

February 5, 2021 - European Journal of Pharmacology, Volume 892, published: COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies.

February 3, 2021 - Preprint study: Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection. The study demonstrated the vaccine candidate's immunogenicity and protective efficacy, ZyCoV-D in rhesus macaques.

February 2, 2021 - Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection.

January 26, 2021 - A non-peer-reviewed study: Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models. The preliminary animal study demonstrates that the candidate DNA vaccine induces antibody response, including neutralizing antibodies against SARS-CoV-2, and provided Th-1 response as evidenced by elevated IFN-γ levels.

January 3, 2021 - Zydus Cadila announced that it would be starting Phase III clinical trials of its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D after receiving permissions from the DCGI. Speaking on the development, Mr. Pankaj R. Patel, Chairman of the Zydus Group, said, “We are reaching a critical milestone in our vaccine development program and towards our goal of helping people fight the pandemic with an indigenously discovered, safe, and efficacious vaccine. The launch of the Phase 3 trial will determine the efficacy of our vaccine in preventing COVID-19 which continues to pose a major threat the world over.”

December 24, 2020 - Zydus Cadila announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D, was found to be safe, well-tolerated, and immunogenic in Phase I/II clinical trials. The company is now planning to initiate Phase III clinical trials in around 30,000 volunteers upon receiving necessary approvals.

July 9, 2020 - COVID-19 Vaccine Development Update.

ZyCoV-D COVID-19 Vaccine Clinical Trials

CTRI/2020/07/026352: A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects. ZyCoV-D was found to be safe, well-tolerated, and immunogenic in the Adaptive Phase I/II clinical trials. 

Clinical Trials

No clinical trials found